Supplementary Figure 6: Etanercept renders glioma cells sensitive to EGFR inhibition.
From: A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
(a-b) GBM9 cells were treated with erlotinib and/or enbrel (1μM) for 72 hours followed by Annexin-FACS assay. Unstained cells represent viable cells. Annexin positive cells are undergoing apoptosis. PI (Propidium iodide) positive cells are undergoing late apoptosis. In “Control” cells are treated with control vehicle (DMSO). The combination treatment decreases the number of viable cells and there is an increase in double stained cells (Annexin+PI Positive). (b) Unstained: Erlotinib vs erlotinib+Enbrel: P =0.0008, t=9.11, d.f.=4; Annexin+PI: Erlotinib vs erlotinib+Enbrel: P=0.0012, t=8.18, d.f.=4. (c-d) A similar experiment was conducted in U87EGFRwt cells with a similar result. (d) Unstained: Erlotinib vs erlotinib+Enbrel: P =0.0006, t=9.6, d.f.=4; Annexin+PI: Erlotinib vs erlotinib+Enbrel: P =0.0003, t=11.34, d.f.=4. Data are presented as mean±s.e.m; **P<0.01, ***P<0.001 using two-tailed unpaired Student's t-test (n =3 biologically independent experimental replicates).
